Psyadon Pharmaceuticals Inc.
Treating Tourette syndrome with a neuronal inhibitor
This article was originally published in Start Up
No new drug has been developed for Tourette syndrome in more than 20 years. Almost all medications prescribed for the condition are given off-label, and none are particularly effective. News reported by Psyadon Pharmaceuticals Inc. in late July 2012 is encouraging to both the patient community and the start-up itself. Psyadon announced that an open-label Phase II study of its candidate ecopipam, which inhibits dopamine via the D1 receptor, was stopped after a planned interim data analysis because the data were strong enough to suggest the compound is conferring a genuine benefit.